Sandoz loses antitrust appeal and Sandoz stock costs EUR 74.47

Published on 10/08/2026 at 11:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sandoz stock stood at EUR 74.47 on October 8, 2026. First-half net sales reached USD 5.8 billion, up 5.00 percent at constant currency.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz Group AG (ISIN CH1243598427) stock stood at EUR 74.47 at Lang & Schwarz on October 8, 2026 at 11:36 a.m. CEST. The latest company-specific legal development was negative: on October 7, 2026, MLex reported that a US appeals court affirmed the dismissal of Sandoz antitrust claims against United Therapeutics over a generic competitor to Remodulin.

Appeal loss adds legal risk

The ruling concerned allegations that United Therapeutics had obstructed the release of a generic treprostinil product by acquiring commercially available cartridges used with a wearable pump. The Third Circuit accepted the companys procompetitive justification, according to MLex.

For Sandoz, the decision matters less as a reported earnings event than as a reminder that litigation can affect the commercial path for generic medicines. The ruling does not change the first-half operating figures, but it adds a legal counterweight to the companys biosimilar growth story.

Growth remains led by biosimilars

In the first half of 2026, Sandoz reported net sales of USD 5.8 billion, up 5.00 percent at constant currency from USD 5.2 billion in the first half of 2025, according to the Yahoo Finance transcript.

Biosimilar sales grew 20.00 percent in the first half of 2026 and represented 33.00 percent of sales. Core EBITDA margin reached 20.90 percent, up 0.90 percentage points from 20.00 percent in the first half of 2025, while core diluted earnings per share rose 17.00 percent to USD 1.71.

Management free cash flow was USD 503 million in the first half of 2026, even as capital spending increased. S&P Global Ratings also cited first-half net sales of USD 5.8 billion and a core EBITDA margin of 20.90 percent.

Stock price and investor view

Sandoz is listed on the SIX Swiss Exchange under the SDZ symbol, according to the company information carried by Finanzen. The combination of 20.00 percent biosimilar growth and a 20.90 percent core EBITDA margin gives the stock a clear operating strength, while the antitrust ruling illustrates the legal risks attached to generic competition.

The reference price was EUR 74.47 at Lang & Schwarz on October 8, 2026 at 11:36 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.